Forest Laboratories Ireland Ltd.

To evaluate the efficacy of a single dose of Atogepant compared with placebo in the treatment of a single acute migraine attack. To evaluate the safety and tolerability of Atogepant in the treatment of acute single and multiple migraine attacks, and to evaluate the consistency of the effect in the treatment of multiple attacks.

Safety and Tolerability: To evaluate the safety and tolerability of atogepant 60 mg once daily for 12 weeks for the prevention of migraine in Chinese participants who have completed Study 3101-303-002 (CM). Efficacy: To evaluate the efficacy of atogepant 60 mg once daily for 12 weeks for the prevention of migraine in Chinese participants with CM.

To evaluate the safety and tolerability of atogepant 30 mg BID and atogepant 60 mg once daily for the prevention of CM. To prospectively test the superiority of atogepant (30 mg BID and atogepant 60 mg once daily) versus placebo for the prevention of CM.